Nvidia's investment arm, NVentures, revealed it owns 833,325 shares in Generate:Biomedicines, valued at around $10.4 million following Nvidia's May 2026 13F filing. Generate, traded under the ticker GENB on Nasdaq, operates an AI-driven platform that automates the creation and enhancement of therapeutic proteins, striving to hasten drug discovery from years to mere months.
#What is Generate:Biomedicines doing in the biotech space?
Generate:Biomedicines employs generative AI technologies to craft proteins and drug candidates directly. The company is beyond initial explorations, currently conducting a Phase 3 clinical trial for severe asthma, a crucial final testing phase before seeking regulatory approval. Additionally, Generate has several oncology candidates designated with FDA Fast Track status, indicating their potential for addressing significant medical needs.
Since its inception, Generate:Biomedicines has successfully raised about $700 million in funding. NVentures first engaged with the firm during its substantial Series C round, which raised $273 million in September 2023, attracting contributions from major players like Amgen before Generate went public via an IPO in February 2026.
#Why is Nvidia focusing on drug design and biotechnology?
The $10.4 million stake represents a modest investment for a tech giant like Nvidia. However, through investments in firms like Generate, Nvidia is nurturing a customer base that will increasingly rely on its powerful chips in coming years. The domain of drug discovery relies heavily on high-performance computing to simulate molecular interactions, predict protein folding, and conduct numerous simultaneous virtual experiments, all of which require the specialized capabilities of Nvidia's technology.
#What does this mean for investors interested in AI and biotech?
Investors must consider the inherent risks associated with backing clinical-stage companies like Generate:Biomedicines. Although the company has secured significant funding, it has yet to yield revenue from approved drugs. Phase 3 trials are known to fail, and while Fast Track designation can expedite development, it does not ensure market approval. Therefore, the financing of approximately $700 million will need to sustain Generate through potentially lengthy clinical endeavors.
For those invested in Nvidia or similar AI infrastructure opportunities, Generate's advancement through clinical trials has become a critical metric to monitor. A positive outcome from the Phase 3 trial concerning severe asthma could impact GENB's stock significantly, enhancing the argument that AI-driven computing is increasingly essential across sectors extending beyond technology, which ultimately supports Nvidia's investment thesis.